Biomea Fusion Inc (BMEA)
12.22
-0.56
(-4.38%)
USD |
NASDAQ |
May 17, 16:00
12.22
0.00 (0.00%)
After-Hours: 20:00
Biomea Fusion Enterprise Value: 295.04M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | 295.04M |
May 16, 2024 | 314.45M |
May 15, 2024 | 330.99M |
May 14, 2024 | 299.72M |
May 13, 2024 | 266.65M |
May 10, 2024 | 237.89M |
May 09, 2024 | 266.29M |
May 08, 2024 | 252.99M |
May 07, 2024 | 286.42M |
May 06, 2024 | 295.76M |
May 03, 2024 | 299.00M |
May 02, 2024 | 283.90M |
May 01, 2024 | 270.96M |
April 30, 2024 | 241.13M |
April 29, 2024 | 241.49M |
April 26, 2024 | 242.56M |
April 25, 2024 | 232.09M |
April 24, 2024 | 242.90M |
April 23, 2024 | 250.46M |
April 22, 2024 | 245.06M |
April 19, 2024 | 244.96M |
April 18, 2024 | 256.10M |
April 17, 2024 | 268.32M |
April 16, 2024 | 284.49M |
April 15, 2024 | 304.61M |
Date | Value |
---|---|
April 12, 2024 | 321.50M |
April 11, 2024 | 332.28M |
April 10, 2024 | 313.59M |
April 09, 2024 | 315.03M |
April 08, 2024 | 304.61M |
April 05, 2024 | 312.52M |
April 04, 2024 | 308.02M |
April 03, 2024 | 356.54M |
April 02, 2024 | 315.03M |
April 01, 2024 | 404.87M |
March 28, 2024 | 359.68M |
March 27, 2024 | 374.40M |
March 26, 2024 | 359.68M |
March 25, 2024 | 372.60M |
March 22, 2024 | 393.06M |
March 21, 2024 | 433.25M |
March 20, 2024 | 389.11M |
March 19, 2024 | 372.61M |
March 18, 2024 | 388.57M |
March 15, 2024 | 463.35M |
March 14, 2024 | 427.13M |
March 13, 2024 | 447.21M |
March 12, 2024 | 383.37M |
March 11, 2024 | 375.84M |
March 08, 2024 | 374.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-75.96M
Minimum
Apr 29 2022
1.393B
Maximum
Jun 08 2023
281.57M
Average
195.02M
Median
Enterprise Value Benchmarks
Poseida Therapeutics Inc | 169.34M |
Cartesian Therapeutics Inc | 366.93M |
BioXcel Therapeutics Inc | 105.18M |
NovaBay Pharmaceuticals Inc | 5.156M |
Palatin Technologies Inc | 22.26M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -39.06M |
Total Expenses (Quarterly) | 41.06M |
EPS Diluted (Quarterly) | -1.09 |
Earnings Yield | -29.17% |